Sun Pharma has signed a definitive agreement to acquire Pola Pharma for $1m.

The acquisition is part of Sun Pharma’s strategy to bolster its presence in the global dermatology market. It will add local manufacturing capabilities to the company and enable it to launch its dermatology products in Japan.

The transaction is expected to be completed by the end of January 2019.

Based in India, Sun Pharma produces generic pharmaceuticals, while Pola Pharma is a Japan-based pharmaceutical company that develops, produces and distributes dermatology products.

Genentech has entered a definitive agreement to acquire Jecure Therapeutics.

The acquisition will add Jecure’s complete portfolio of NLRP3 inhibitors. It will enable the company to combine Jecure’s research and development capabilities with its expertise in NLRP3 biology to develop therapeutics for inflammatory diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
CVS Health has completed the acquisition of Aetna for $78bn.”

Roche Group subsidiary Genentech is a biotechnology and pharmaceutical company, while Jecure Therapeutics is a biotechnology company engaged in the discovery of novel therapeutics for the treatment of non-alcoholic fatty liver disease and liver fibrosis. Both companies are based in the US.

CVS Health has completed the acquisition of Aetna for $78bn.

The company exchanged each outstanding share of Aetna common stock for $145 in cash and 0.8378 shares of CVS Health common stock.

The transaction was funded by existing cash on hand and debt financing. It is expected to generate synergies worth $750m by 2020 and support CVS Health’s growth plans.

The acquisition will create a combined company, which will deliver an innovative healthcare model to patients. Aetna will operate as a standalone company operating under CVS Health.

CVS Health is a pharmacy innovation company, while Atena is engaged in health insurance plans and dental coverage. Both companies are based in the US.